DUBLIN–(BUSINESS WIRE)–The “Ascites – Epidemiology Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Number of Ascites Cases due to Cirrhosis, Number of Ascites Cases by Malignancies, and Severity-specific Cases of Ascites due to Cirrhosis scenario of Ascites in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
Ascites Detailed Epidemiology Segmentation
- In 2020, the total cases of Ascites due to cirrhosis in the 7MM was 240,730, which is likely to increase by 2030 at a CAGR of 0.61% for the study period (2018-2030).
- Malignant Ascites cases are calculated from ovarian cancer, stomach cancer, breast cancer, and colorectal cancer. In 2020, The number of cases of Ascites from these cancers was 8,521; 3,538; 12,650; and 10,276, respectively, in the US.
- According to the publisher’s analysis, in 2020, there were 26,841 and 122,277 cases of Grade I and Grade II & III ascites due to cirrhosis in the United States.
- Among the EU-5 countries, the highest cases of Ascites due to cirrhosis were found in Germany (20,004), followed by the UK (15,845) and France (11,138). The least cases of Ascites due to cirrhosis were found in Spain (4,904).
- There were 29,571 cases of ascites due to cirrhosis in Japan in 2020.
Scope of the Report
- The report covers the descriptive overview of Ascites, explaining its causes, signs, and symptoms, and pathophysiology.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
- The report assesses the disease risk and burden.
- The report provides the segmentation of the disease epidemiology for 7MM by Number of Ascites Cases due to Cirrhosis, Number of Ascites Cases by Malignancies, and Severity-specific Cases of Ascites due to Cirrhosis.
- 10-Year Forecast of Ascites
- 7MM Coverage
- Number of Ascites Cases due to Cirrhosis
- Number of Ascites Cases by Malignancies
- Severity-specific Cases of Ascites due to Cirrhosis
Key Questions Answered
- What are the disease risk, burdens, and unmet needs of Ascites?
- What is the historical Ascites patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Ascites at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Ascites?
- Out of the countries mentioned above, which country would have the highest patient population of Ascites during the forecast period (2021-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Ascites Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of Ascites due to Cirrhosis in 2018
3.2. Epidemiology Share (%) Distribution of Ascites due to Cirrhosis in 2030
4 Executive Summary of Ascites
5 Disease Background and Overview
5.2. Types of ascites and underlying primary diseases
5.3. Causes of Ascites
5.4. Symptoms of Ascites
5.5. Pathogenesis of Ascites
5.6. Diagnosis of Ascites
5.6.2. Physical examination
5.6.3. Blood tests
5.6.4. Abdominal ultrasound
5.6.5. Abdominal paracentesis
5.6.6. Visual inspection
5.6.7. Biochemical testing
5.6.8. Nonbiochemical testing
5.6.9. Diagnostic Algorithm
5.7. Diagnostic Guidelines of Ascites
5.7.1. British Society of Gastroenterology and the British Association for the Study of the Liver Guidelines
5.7.2. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
5.7.3. American Association for the Study of Liver Diseases (AASLD) Management of Adult Patients with Ascites Due to Cirrhosis
6 Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology for the Epidemiology of Ascites
6.3. Total Cases of Ascites due to Cirrhosis in the 7MM
6.4. Epidemiology of Ascites
7 KOL Views
For more information about this report visit https://www.researchandmarkets.com/r/iar7l7
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900